1. FDA approves Sarepta’s DMD drug that it had previously rejected — Biogen chalks up another failure — The House passes the Lower Drug Costs Now Act, but it’s unlikely to become law — See more on our front page news

    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Goodbye KCHC

Discussion in 'Kimberly-Clark' started by Anonymous, Nov 15, 2014 at 9:47 AM.

  1. Anonymous

    Anonymous Guest

    Goodbye to the failed experiment known as KCHC. Goodbye to the failures in upper management, all the K-C paper people that were brought here with no knowledge of how to run a medical device company, the failed vision, the failed products, and failed bus that burst into flames, to all the failed product designs, the failed processes, the failed roofs that collapsed at our ONLY DC.
    And although many of the losers were brought over to Halyard, I think this actually might work.
  2. Anonymous

    Anonymous Guest

    Well said. I too am hoping for a bright new day. I'm going to stick it out. Why not? Only upside as far as I am concerned.

    Next year will tell a lot.

    Raise the sails!
  3. Anonymous

    Anonymous Guest

    no same old people every is still the same